Previous Close | 71.28 |
Open | 72.06 |
Bid | 74.29 x 300 |
Ask | 74.48 x 1500 |
Day's Range | 71.90 - 75.00 |
52 Week Range | 61.16 - 85.57 |
Volume | |
Avg. Volume | 936,933 |
Market Cap | 11.82B |
Beta (5Y Monthly) | 1.28 |
PE Ratio (TTM) | 78.31 |
EPS (TTM) | 0.95 |
Earnings Date | Jan 30, 2025 - Feb 03, 2025 |
Forward Dividend & Yield | 0.32 (0.43%) |
Ex-Dividend Date | Nov 08, 2024 |
1y Target Est | 85.25 |
Gemini Bioproducts, LLC ("GeminiBio"), a leading supplier of cell culture reagents and process liquids, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, today announced the acquisition of selected fetal bovine serum (FBS) product rights and inventory from Bio-Techne (NASDAQ: TECH).
Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates.